Sclerosis multiplex (SM): ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD20 17
• CD19 10
• PPAR 0
• NLRP3 0
• STAT3 0
• BCMA 13
• BTK 1
• IL-17 0
• NRF2 0
• TNF 0
• AQP4 0
• GLP-1 2
• AMPK 0
• BDNF 1
• AKT 0
• IL-6 0
• mTOR 0
• CD40 0
• JAK 0
• PI3K 0
• STING 0
• TREM2 0
• PD-1 0
• IL-1 0
• IL-4 0
• SIRT1 0
• TLR4 0
• AXL 0
• CGRP 0
• CSF1R 0
• HIF-1 0
• IL-23 0
• VEGF 1
• COX-2 0
• CTLA-4 0
• CXCR4 0
• ERK 0
• HMGB1 0
• HSP90 0
• PD-L1 0
• TYK2 1
• APOE 0
• CCR5 0
• CTNNB1 0
• EGFR 0
• FOXP3 0
• GPX4 0
• IDO1 0
• JNK 0
• PARP 0
• PTEN 0
• TP53 1
• ACE2 0
• APP 0
• BCL-2 0
• BRD4 0
• C9orf72 0
• CDK4/6 0
• G6PD 0
• HDAC 0

12+ intézményből 12, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Artificial intelligence and WeArables for the undeRstanding and Evaluation of Multiple Sclerosis (AWARE-MS)

  Scuola Superiore di Studi Universitari e di Perfezionamento S Anna· Pisa, Olaszország· EU contribution 420 751 EUR· until 2030. márc.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Astrocytic exhaustion underlies chronic progression in autoimmune inflammation of the central nervous system (AXhaustMS)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Németország· EU contribution 1 638 843 EUR· until 2032. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Molecular regulation of the axon–myelin interface in development and repair (MInDRe)

  The University of Edinburgh· Edinburgh, Egyesült Királyság· EU contribution 260 348 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Harnessing engineered lipid nanoparticles to tame autoimmune neuroinflammation by inducing regulatory T cells through CNS myeloid reprogramming (LipoTAME)

  Vrije Universiteit Brussel· Bruxelles / Brussel, Belgium· EU contribution 200 400 EUR· until 2029. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Targeting myeloid cell states, actions and interactions in neuroinflammation (TACO)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Németország· EU contribution 2 471 050 EUR· until 2031. dec.

5 of 46 running projects, newest first. Listed amounts together: 130,5 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Sanofi· Forrás

• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

  NCT04410978· Sanofi· Forrás

• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

  NCT04410991· Sanofi· Forrás

• Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

  NCT04411641· Sanofi· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 16
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 3
• Gene Expression Profiling 39
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 34
• Metabolomics 21
• Mass Spectrometry 12
• Flow Cytometry 29
• Immunohistochemistry 10
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 29
• Magnetic Resonance Imaging 570
• Machine Learning 43
• Deep Learning 33
• Cohort Studies 183
• Genome-Wide Association Study 84

• Antigen presentation by CD40+MHC-II+ astrocytes promotes CNS autoimmunity.

  Nature, 2026. aug.

  Francisco J Quintana

• CRISPR-Based Gene Therapy for Brain Disease.

  Mol Neurobiol, 2026. jún.

• In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation.

  Nat Neurosci, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.